AURA
Aura Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.44
−2.28%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$6.53
From 52W high−27.64%
Volume3.78M
Market cap$667.86M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$6.53
From 52W high
−27.64%
Volume
3.78M
Market cap
$667.86M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.7x
P/E (TTM)
—
RSI (14)
33.7
MomentumView details →
1D Return
−2.28%
YTD Return
+21.56%
SummaryUpdated Jun 1, 2026
Aura Biosciences, Inc. (NASDAQ:AURA) is a clinical-stage biotechnology company founded in 2009 and headquartered in Cambridge, Massachusetts. The company went public in October 2021 and focuses on developing innovative cancer therapies using its proprietary virus-like drug conjugate (VDC) technology platform. Aura specializes in treating rare and difficult-to-treat cancers, particularly in ocular (eye-related) and urologic oncology where significant unmet medical needs exist.
Similar companies
Latest newsMore news →
Aura Biosciences reported a net loss of $45.6 million for Q2 2026, with diluted EPS of -$0.48, and announced a 20% workforce reduction as part of an organizational realignment, expecting cash runway into the first half of 2029.41d agoAura Biosciences appointed Jeremy Bender as a Class II director effective July 7, 2026.75d ago